Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Moderna has said it expects to be able to produce about 20 million doses of mRNA-1273 in 2020 and from 500 million up to one billion doses worldwide in 2021.
Citing a spike in COVID-19 cases across clinical sites, Moderna (NASDAQ:MRNA) announces that the first interim analysis of results from the large-scale pivotal study, COVE, of vaccine candidate mRNA-1273 will include "substantially more" that the 53 cases it was expecting (the higher the number the better). Case accrual has been completed for the readout. The dataset is being prepared for submission to the independent Data Safety Monitoring Board.
Enrollment was completed on October 22.
The company remains blinded to the data.
The efficacy bar has been set by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). Their candidate, BNT162b2, showed 90% efficacy based on 94 confirmed cases.
Shares up 1% after hours.
Waiting for PERCENT EFFECTIVE NUMBER.
Nov 9 up=9 down=0 bullih
NOV 6 …….UP 7 DOWN = 2 BULLISH
So where is the news ??
(Reuters) - Moderna Inc said on Tuesday United Kingdom’s health regulator has started a real-time review of its experimental COVID-19 vaccine candidate.
The company has begun a rolling data submission from its vaccine candidate to UK’s Medicines and Healthcare products Regulatory Agency (MHRD) for it to start its independent assessment of evidence as and when it becomes available.
Such a process allows for a reduced time to approve a treatment, while maintaining the same standards of safety and effectiveness.
Moderna said earlier this month it was going to apply for real-time reviews of its experimental COVID-19 vaccine to Europe, following rolling reviews of shots of its rivals Pfizer Inc and AstraZeneca.
Canada's health ministry is also in the process of reviewing Moderna's COVID-19 vaccine candidate in real time, the company said earlier this month. (reut.rs/3kztkvr)
Reporting by Trisha Roy in Bengaluru; Editing by Shinjini Ganguli
Our Standards: The Thomson Reuters Trust Principles.
Moderna (MRNA) Scheduled to Post Quarterly Earnings on Thursday
Moderna (NASDAQ:MRNA) is set to post its quarterly earnings results before the market opens on Thursday, October 29th.
The Zacks Consensus Estimate for collaboration revenues for the third quarter is pegged at $16.76 million
MCAP=76B
DIV = 2.52
EPS = 4.21
Looks like Remdisiver was already priced into the stock.
Do you agree that phase 3 ends on December 22, 2020?
(Bloomberg) -- A participant who died during a trial of AstraZeneca Plc’s Covid-19 vaccine in Brazil hadn’t received the company’s shot, according to a person familiar with the matter.
ONE DIES IN TRIAL
10/21/20 BREAK OUT FOR TODAY IS 146
The 8 trades added up to 24.55
Not bad for a month. IMHO.
I do not play options.
Pfizer and its German partner BioNTech could apply for emergency-use authorization for their COVID-19 vaccine in late November, Pfizer said Friday.
10% winners no
10% still have some money left
SEC STUDY SAYS "90% of the option players lose all their money in the first year."
ART HILL says go long or stay out.
Shorts never make money in the long run.
This is based on his 20 year studies.
But I am sure you make tons of money.
The key is 141.94 A trade below that number then the trend is down.
SPY and QQQ are still leading year-to-date. These two recorded new highs in late August and early September. After falling wedge corrections that retraced almost 2/3 of the June-September advance, these two broke out and followed through on these breakouts. They have yet to exceed their early September highs, but the breakouts are bullish until proven otherwise. A move below 330 in SPY and 270 in QQQ would negate the breakouts and put the correction theme back on the table.
BY ART HILL
Well I in cash right now.
So maybe I will stop trading.
Since 9/29/20 gain = 15.5 % including Today's loss.
I am sure you made more in the last 14 trading days.
SELL AT THE CLOSE 10/15/22
I AM WOKING ON THE BUY YESTERDAY AT THE CLOSE.
red candle today
Hold for WC on 10/15
SELL at 5% gain
or at the close on 10/14/20
Bought at the close
Another vaccine trial on pause. This time it’s J&J’s which is using a non-replicating adenovirus platform like the AstraZeneca vaccine that is currently halted in the US.
https://www.nytimes.com/live/2020/10/13/world/coronavirus-covid#johnson-johnson-pauses-its-coronavirus-vaccine-trial-because-of-a-volunteers-unexplained-illness
Still room for TQQQ to rise.
Top above RSI 14 = 70
Presently RSI 14 = 64
JnJ vaccine put on hold
Watch Rsi((14) = 30 and NDXHLP returns to zero